AbCellera Biologics Hits New 52-Week High of $6.79, Up 84%

AbCellera Biologics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 6.79 on June 1, 2026. This achievement marks a remarkable performance increase of 84.05% over the past year, significantly outpacing the S&P 500's growth of 28.56% during the same period. As a small-cap company in the Pharmaceuticals & Biotechnology sector, AbCellera has a market capitalization of USD 1,079 million. Despite its recent price surge, the company remains in a loss-making position, with a negative return on equity of -17.81%. The stock's price-to-book ratio stands at 1.12, indicating its valuation relative to its net assets. AbCellera's financial metrics reflect a unique position within its industry, characterized by a debt-to-equity ratio of -0.53 and a lack of dividend yield. The stock's previous 52-week low was recorded at USD 2.02, highlighting the substantial growth it has experienced over the past year.